Luke Davis
Nurse Practitioner · Baton Rouge, LANPI 1427408574
Payments from drug & device makers
Across 320 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$653
- Johnson & Johnson$615
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$575
- Merck$474
- Pfizer$461
- Amgen$370
- plus $3K from 27 others
What the payments were for
- Food & beverage$6,066100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 45 | $653 |
| Johnson & Johnson | 42 | $615 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 36 | $575 |
| Merck | 28 | $474 |
| Pfizer | 26 | $461 |
| Amgen | 23 | $370 |
| AOP Health US, LLC | 1 | $369 |
| AstraZeneca | 15 | $284 |
| Alnylam Pharmaceuticals Inc. | 10 | $266 |
| Esperion Therapeutics, Inc. | 13 | $220 |
| Boehringer Ingelheim | 7 | $217 |
| Boston Scientific | 8 | $173 |
| Irhythm Technologies, Inc. | 8 | $160 |
| Novo Nordisk | 8 | $145 |
| Medtronic | 1 | $132 |
| E.r. Squibb & Sons, L.L.C. | 6 | $94 |
| Amarin Pharma, Inc. | 5 | $92 |
| Bayer | 5 | $89 |
| Abbott | 3 | $87 |
| Abiomed | 4 | $77 |
| Azurity Pharmaceuticals, Inc. | 4 | $76 |
| Cvrx, Inc. | 2 | $67 |
| Baxter Healthcare | 2 | $63 |
| Scpharmaceuticals Inc. | 3 | $59 |
| Kowa Pharmaceuticals America, Inc. | 3 | $46 |
| Arbor Pharmaceuticals, Inc. | 3 | $44 |
| Kestra Medical Technology Services, Inc. | 2 | $38 |
| Lexicon Pharmaceuticals, Inc. | 2 | $33 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $16 |
| Edwards Lifesciences | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,066 in reported general payments places this provider in the 90th percentile of 969 nurse practitioner providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 352 | $315,686 |
| EntrestoSacubitril/Valsartan | 257 | $238,903 |
| XareltoRivaroxaban | 128 | $105,445 |
| JardianceEmpagliflozin | 122 | $87,521 |
| FarxigaDapagliflozin Propanediol | 97 | $67,293 |
| Repatha SureclickEvolocumab | 57 | $44,322 |
| Repatha SyringeEvolocumab | 24 | $17,058 |
| Praluent PenAlirocumab | 23 | $14,849 |
| VerquvoVericiguat | 16 | $12,496 |
| Metoprolol Succinate | 749 | $10,721 |
| OzempicSemaglutide | 12 | $10,362 |
| BrilintaTicagrelor | 19 | $9,217 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $7,741 |
| Bumetanide | 137 | $5,763 |
| Valsartan | 175 | $5,043 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $461 | $315,686352 claims |
| NovartisEntresto | $653 | $238,903257 claims |
| Johnson & JohnsonXarelto | $615 | $105,445128 claims |
| Boehringer IngelheimJardiance | $217 | $87,521122 claims |
| AstraZenecaFarxiga, Brilinta | $284 | $76,509116 claims |
| MerckVerquvo | $474 | $12,49616 claims |
| Novo NordiskOzempic | $145 | $10,36212 claims |
| Esperion Therapeutics, Inc.Nexlizet | $220 | $7,74112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 969 nurse practitioner providers in Louisiana.
Other nurse practitioner in Baton Rouge
- Sara FrankBaton Rouge$14K
- Jasmine SpearmanBaton Rouge$13K
- Morgan HoffmanBaton Rouge$12K
- Breanna ByrdBaton Rouge$9K
- Ashley AmedeeBaton Rouge$9K
- Judson JonesBaton Rouge$9K
- Emily Santa AnaBaton Rouge$7K
- Allyson DupreBaton Rouge$7K
- Karen DeshotelLafayette$264K
- Christopher ManuelKaplan$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.